Side-by-side · Research reference
CerebrolysinvsFollistatin-344
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED11/65 cited
BHuman-MechanisticHUMAN-REVIEWED4/58 cited
Cerebrolysin
Porcine Brain-Derived Peptide Mix · Phase 3
14–21 daysTreatment course
IV infusion · 100-250 mL saline · Daily
Follistatin-344
Myostatin/Activin Antagonist · Research Use
15–25%FST/MSTN ratio ↑
344 AACirculating isoform
ResearchPhase status
Research · No approved protocol
01Mechanism of Action
Parameter
Cerebrolysin
Follistatin-344
Primary target
Multiple neurotrophic pathways — mimics BDNF, NGF, CNTF receptor activation
Myostatin (MSTN/GDF-8) and Activin A
Pathway
Cerebrolysin peptides → BDNF/NGF/CNTF receptor binding → TrkB/TrkA/LIFR signaling → neuroprotection, neuroplasticity, synaptogenesis
FST-344 binds MSTN/Activin → prevents ActRIIB receptor engagement → disinhibits muscle anabolism
Downstream effect
Reduced apoptosis (Bax ↓, Bcl-2 ↑), suppressed TNF-α inflammation, elevated endogenous BDNF, enhanced synaptic plasticity and motor recovery
Elevated follistatin/myostatin ratio, increased muscle protein synthesis, attenuated muscle atrophy signalingJeong 2026
Feedback intact?
Yes — exogenous peptides do not suppress endogenous neurotrophic factor synthesis
Yes — indirect antagonist, preserves endogenous regulation
Origin
Enzymatic breakdown of lipid-free porcine brain proteins → standardized low-MW peptide fraction (<10 kDa) + free amino acids
Endogenous glycoprotein, 344-AA isoform lacking heparin-binding domain (vs FST-315)
Antibody development
Not reported in human trials; porcine origin theoretically immunogenic but no clinically significant allergic reactions documented
Not documented in available trials (endogenous protein)
02Dosage Protocols
Parameter
Cerebrolysin
Follistatin-344
Standard dose (stroke)
30–50 mL / day IVStaszewski 2026Afridi 2026
Most trials use 30 mL in 100-250 mL saline over 30-60 min.
—
Lower dose (dementia)
10–20 mL / day IV or IMKhatkova 2026
Chronic neurodegenerative conditions; intermittent courses.
—
Duration
10–21 days (acute); intermittent courses (chronic)
Stroke trials typically 10-14 days; rehabilitation phases may use repeated 10-day courses.
—
Timing (stroke)
Initiate within 12 hrs of symptom onset; up to 6 hrs optimal
Earlier initiation associated with better outcomes.
—
Adjunct to thrombectomy
30-50 mL daily × 10-14 days, starting day of EVT
Propensity-matched data show 12-mo mRS 0-2 improved from 35% to 49%.
—
Evidence basis
Phase 3 RCT + observational
Human observational / biomarker studies
Administration route
IV infusion (preferred) or IM injection
IV allows higher doses; IM used in outpatient/chronic settings.
—
Clinical protocol
—
None — no approved dosing regimen
Follistatin-344 measured as endogenous biomarker, not administered exogenously in cited trials.
Research context
—
Endogenous modulation via exercise + nutrition
Resistance training + EAA intake elevated FST/MSTN ratio by 15–25% in 12-week RCT (older women).
Half-life
—
Not established
Circulating isoform; lacks tissue-binding domain of FST-315.
03Metabolic / Fat Loss Evidence
Parameter
Cerebrolysin
Follistatin-344
Primary target
—
Muscle mass preservation, not direct lipolysis
Indirect fat effect
—
Increased lean mass → elevated resting metabolic rate
Not primary mechanism. Muscle-sparing during deficit.
Clinical evidence
—
Lorcaserin trial (6 mo) showed no MAFI axis changes during fat lossRamirez-Cisneros 2026
Suggests follistatin not primary driver of fat loss in weight-reduction interventions.
GLP-1RA studies
—
Liraglutide (35 days) — no significant MAFI axis modulation despite fat/lean changes
04Side Effects & Safety
Parameter
Cerebrolysin
Follistatin-344
Injection site reaction
Mild pain, erythema (IM route)
—
Infusion reaction
Rare: flushing, transient hypotension during rapid IV
—
Agitation / Restlessness
Reported in <5% of patients; typically mild, self-limited
—
Serious adverse events
No significant increase vs placebo (RR 1.02, 95% CI 0.87-1.20)
—
Hemorrhagic transformation
Reduced incidence vs control (52% reduction in high-risk post-thrombolysis cohort)Kalinin 2025
—
Mortality
No increase; meta-analysis RR 0.89 (0.68-1.18)
—
Allergic reaction
Rare; porcine origin theoretically immunogenic but clinically insignificant
—
Seizure risk
Not elevated; safe in epilepsy populations
—
Clinical safety data
—
None — no human exogenous administration trials in literature
Theoretical risks
—
Excessive myostatin inhibition → muscle overgrowth, impaired glucose tolerance
Based on myostatin-null animal models and clinical myostatin inhibitor trials.
Endogenous elevation (exercise)
—
No adverse effects reported in 12-week resistance + EAA trials
Cancer risk (theoretical)
—
Myostatin inhibition may promote tumor growth in malignancy (preclinical data)
Regulatory status
—
Not approved for human use — research peptide only
Absolute Contraindications
Cerebrolysin
- ·Known hypersensitivity to porcine-derived products
- ·Active seizure disorder (relative — caution advised)
Follistatin-344
- ·Active malignancy
- ·No approved protocol — research use only
Relative Contraindications
Cerebrolysin
- ·Severe renal impairment (amino acid load — monitor)
- ·Pregnancy / lactation (insufficient safety data)
Follistatin-344
- ·Insulin resistance / Type 2 diabetes (monitor glucose)
- ·Pregnancy / lactation (unknown safety profile)
05Administration Protocol
Parameter
Cerebrolysin
Follistatin-344
1. Preparation (IV infusion)
Dilute prescribed dose (10-50 mL) in 100-250 mL 0.9% sodium chloride. Use immediately after preparation. Do not mix with other medications in same infusion bag.
Follistatin-344 is not approved for human administration. All cited studies measure endogenous serum follistatin as a biomarker, not as an exogenous therapeutic agent.
2. Infusion rate
Administer over 30-60 minutes. Slower infusion reduces risk of transient hypotension or flushing. Monitor vital signs during first administration.
Resistance exercise combined with essential amino acid (EAA) supplementation elevated the follistatin/myostatin ratio by 15–25% in 12-week randomized trials. Protein intake (1.2–1.5 g/kg/day) synergizes with training to upregulate endogenous follistatin.
3. IM injection (alternative)
For 5-10 mL doses: inject deep IM into gluteal or deltoid muscle. Rotate sites if repeated daily. IM preferred for outpatient/chronic use.
Serum follistatin and follistatin/myostatin ratio are used diagnostically in sarcopenia screening and as biomarkers of muscle anabolic balance in clinical trials.
4. Timing
Acute stroke: initiate within 6-12 hrs of symptom onset. Daily administration, preferably same time each day. Continue 10-21 days per protocol.
Gene therapy and recombinant follistatin delivery are under preclinical investigation for muscular dystrophy and sarcopenia. No human safety or efficacy data for exogenous FST-344 administration.
5. Storage
Store unopened ampoules at 15-25°C, protected from light. Do not freeze. Use diluted solution immediately; discard unused portion.
—
6. Co-administration
Compatible with standard stroke care (thrombolysis, thrombectomy, antiplatelet/anticoagulant therapy). Does not interfere with reperfusion therapies.
—
06Stack Synergy
Cerebrolysin
+ Semax
ModerateCerebrolysin (multimodal neurotrophic peptide mix) and Semax (ACTH(4-10) analogue) operate through complementary neuroprotective pathways. Cerebrolysin elevates BDNF and suppresses apoptosis/inflammation via TrkB/TrkA signaling, while Semax enhances neuroplasticity through BDNF upregulation and dopaminergic modulation. Combined use in stroke or TBI may amplify anti-apoptotic effects and accelerate cognitive/motor recovery, though no direct RCT data exist for the combination.
- Cerebrolysin
- 30 mL IV daily × 10-14 days
- Semax
- 300-600 mcg intranasal BID × 10-14 days
- Timing
- Concurrent during acute recovery phase
- Primary benefit
- Enhanced neuroprotection, accelerated motor/cognitive recovery post-stroke or TBI
+ BPC-157
Multi-pathwayCerebrolysin provides CNS-specific neurotrophic support (BDNF, NGF pathways), while BPC-157 offers systemic tissue repair via angiogenesis (VEGF upregulation) and anti-inflammatory effects. In traumatic brain injury or stroke, Cerebrolysin addresses neuronal survival and synaptic plasticity, whereas BPC-157 may enhance vascular repair and blood-brain barrier integrity. The combination targets both neuronal and vascular compartments of brain injury, though clinical validation is lacking.
- Cerebrolysin
- 30-50 mL IV daily × 14 days
- BPC-157
- 250-500 mcg SQ daily × 14-28 days
- Timing
- Initiate both within 24-48 hrs of injury
- Primary benefit
- Dual neuronal + vascular repair in TBI or stroke; accelerated functional recovery
Follistatin-344
+ BPC-157
Multi-pathwayFollistatin-344 (myostatin antagonist) and BPC-157 (tissue repair peptide) address complementary pathways in muscle recovery. FST-344 promotes muscle protein synthesis by disinhibiting myostatin signaling, while BPC-157 accelerates healing of tendons, ligaments, and microtears via angiogenesis and collagen synthesis. Combined, they may support both hypertrophy and structural repair during high-volume training or injury recovery.
- Follistatin-344
- No approved protocol — endogenous modulation via resistance exercise + EAA
- BPC-157
- 250–500 mcg SQ · twice daily · near injury site or systemic
- Duration
- 4–8 weeks
- Primary benefit
- Muscle hypertrophy + accelerated soft tissue repair
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) promotes cell migration, angiogenesis, and anti-inflammatory signaling in muscle and connective tissue. Follistatin-344's anabolic signaling may synergize with TB-500's regenerative effects during muscle damage or overtraining, particularly in older adults where both myostatin inhibition and tissue repair are rate-limiting.
- Follistatin-344
- Endogenous upregulation (resistance training + protein)
- TB-500
- 2–5 mg SQ · twice weekly · loading phase 4 weeks, then maintenance
- Frequency
- Twice weekly TB-500, daily training stimulus for FST
- Primary benefit
- Enhanced recovery, reduced inflammation, muscle growth support